Theragnostic Talks

From academia to start-up

It takes persistence to turn preclinical research into business. And it takes great teamwork to make it successful. In this episode of Theragnostic Talks we get to meet Dr Frances Johnson and Dr Michael Schultz. They founded Viewpoint Molecular Targeting, a radiopharmaceutical company with a theragnostic portfolio. Hear them talk about challenges along the way and why they believe in Alpha emitting isotopes. Enjoy!

Guests: Dr Frances Johnson, Dr Michael Schultz
By: Annette Andrén and Gustav Widar
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

ProPSMA and TheraP ­– changing patient care - with Michael Hofman

Professor Michael Hofman has contributed to some of the most important progress for imaging and treatment of prostate cancer. And his collaborative approach has brought together multi-disciplinary expertise from more than 10 centers around Australia.

– If you have the energy to put together a clinical trial protocol I bet colleagues around your country will be happy to adopt it. It is a win-win for everyone.

Please join us in this episode of Theragnostic Talks.

 

Guest: Prof. Michael Hofman
By: Annette Andrén and Gustav Widar
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

The lucky, PET-addicted guy – with Stefano Fanti

By collaboration we can improve the scientific results and really make a difference. Don't miss this episode with the committed professor Stefano Fanti, devoted to his mission and always eager to spread the word about PET and prostate imaging. Ending up with breaking news about the EANM congress… Enjoy!

Guest: Prof. Stefano Fanti
By: Annette Andrén and Gustav Widar
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

Turned family loss to stronger patient voice – with Simone Leyden

When Simone Leyden lost her 34 year old sister in a rare GI cancer she and her brother John decided to start a foundation. What struck them, when their sister was struggling, was that there was a huge difference in treatment and support for less common cancers, compared to more common ones. Please join us and listen to this episode of Theragnostic Talks Simone, founder and CEO of NeuroEndocrine Cancer.

Guest: Simone Leyden, co-founder and CEO NeuroEndocrine Cancer
By: Gustav Widar & Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

”This is the theragnostic breakthrough” – with Oliver Sartor, Bernd Krause and Ken Hermann

We gathered up with Oliver Sartor, Bernd Krause and Ken Hermann, co-authors of the VISION study, to talk about how it will impact the treatment of prostate cancer. The VISION study is the first international randomized open label phase III study that shows convincing results for a novel treatment of late-stage advanced prostate cancer. A targeted treatment for prostate cancer using radioactive 177Lu-PSMA-617. Successful? Without a doubt if you ask Oliver Sartor.

– This is the theragnostic breakthrough we all have been waiting for. It's going to change the way we treat cancer.

Join us on Theragnostic Talks!

 

Guest: Oliver Sartor, Bernd Krause, Ken Hermann
By: Gustav Widar
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

ImmunoPET, predicting response to therapy - with Anna Wu

What is immunoPET and radio immunotherapy? Meet Anna Wu, professor at City of Hope and research professor at UCLA, California. She explains why antibodies can be used instead of small molecules or peptides, how to use immunoPET for patient selection in immunotherapy and why a revolution of precision health is on its way.

Guest: Anna Wu
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

Renaissance for radioligand therapy - with Germo Gericke

In 5 to 10 years we are going to use theragnostics predominantly in combination with other therapies. Why? Because it gives us the opportunity to treat cancer in a totally different way. It's also a step forward to more personalized treatment. In this episode of Theragnostic Talks you get to meet Germo Gericke, Medical Officer at AAA. Enjoy!

We apologize for bad sound quality in the beginning of this episode, but hold on – it gets better after 10 minutes.

Guest: Germo Gericke
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

The PSMA take off - with Professor Louise Emmett

What professor Louise Emmett really loves is research. As a doctor, she says, you are able to change the lives for some people. With clinical research you can change the lives for millions of people. In this episode Louise Emmett explains theragnostics in prostate cancer and how prostate imaging can be used to understand the phenotype of the tumor. A step towards a more personalized treatment.

Guest: Professor Louise Emmett
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

Kill them all - with Dr Oliver Sartor

What are the challenges for theragnostic to be successful in the future? And how can we turn theragnostic innovations into successful and available therapies? In this episode of Theragnostic Talks we talk to Dr Oliver Sartor, the world-renowned prostate cancer expert and leader of Tulane's Prostate Cancer Research Program. Please join!

 

Guest: Dr Oliver Sartor
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se

S01E03 Christian Behrenbruch

“For nuclear medicine to be widely successful you have to care about people everywhere. We need to come up with solutions that make nuclear medicine really accessible for everyone. And the reason why we should do that is because it has a great cost beneficial profile”. The serial entrepreneur Dr Christian Behrenbruch is co-founder and CEO of Telix Pharmaceuticals and our guest in this episode of Theragnostic Talks. Enjoy!

 

Guest: Dr Christian Behrenbruch
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se